Targeting Leukocyte Trafficking in Inflammatory Bowel Disease: What Is the Clinical Evidence?

2015 ◽  
Vol 33 (Suppl. 1) ◽  
pp. 95-104
Author(s):  
Reena Khanna ◽  
Mahmoud H. Mosli ◽  
Brian G. Feagan
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
Cellular Migration ◽  
Leukocyte Trafficking ◽  
Intestinal Tissue ◽  
Efficacy Data ◽  
Inflammatory Bowel ◽  
Inflammatory Drugs ◽  
Novel Targets

Since the cause of inflammatory bowel disease (IBD) is unknown, therapy has traditionally been based on the empiric use of anti-inflammatory drugs. However, the recent identification of specific mechanisms that regulate cellular migration into inflamed intestinal tissue has provided novel targets for drug development. In this article, we discuss these mechanisms and review emerging safety and efficacy data regarding use of selective inhibitors of leukocyte trafficking for the treatment of IBD.

Experimental and Clinical Evidence of Endothelial Dysfunction in Inflammatory Bowel Disease

2020 ◽  
Vol 26 (30) ◽  
pp. 3733-3747 ◽  
Author(s):  
Mariana Ferreira-Duarte ◽  
Joana Beatriz Sousa ◽  
Carmen Diniz ◽  
Teresa Sousa ◽  
Margarida Duarte-Araújo ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Endothelial Dysfunction ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
High Cardiovascular Risk ◽  
Considerable Evidence ◽  
Chronic Inflammatory Condition ◽  
Inflammatory Bowel ◽  
Repurposed Drugs ◽  
Main Effects

The endothelium has a crucial role in proper hemodynamics. Inflammatory bowel disease (IBD) is mainly a chronic inflammatory condition of the gastrointestinal tract. However, considerable evidence points to high cardiovascular risk in patients with IBD. This review positions the basic mechanisms of endothelial dysfunction in the IBD setting (both clinical and experimental). Furthermore, we review the main effects of drugs used to treat IBD in endothelial (dys)function. Moreover, we leave challenging points for enlarging the therapeutic arsenal for IBD with new or repurposed drugs that target endothelial dysfunction besides inflammation.

scholarly journals Prevalence of Self-Reported Spondyloarthritis Features in a Cohort of Patients with Inflammatory Bowel Disease

2013 ◽  
Vol 27 (4) ◽  
pp. 199-205 ◽  
Author(s):  
Carmen Stolwijk ◽  
Marieke Pierik ◽  
Robert Landewé ◽  
Ad Masclee ◽  
Astrid van Tubergen
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Musculoskeletal Symptoms ◽  
Inflammatory Back Pain ◽  
Early Referral ◽  
History Of ◽  
Seronegative Spondyloarthritis ◽  
Inflammatory Bowel ◽  
Inflammatory Drugs ◽  
Or History

BACKGROUND: Musculoskeletal symptoms belonging to the spectrum of ‘seronegative spondyloarthritis’ (SpA) are the most common extraintestinal manifestations in patients with inflammatory bowel disease (IBD) and may lead to important disease burden. Patients with suspected SpA should be referred to a rheumatologist for further evaluation.OBJECTIVE: To investigate the self-reported prevalence of musculoskeletal SpA features in a cohort of patients with IBD and to compare this with actual referrals to a rheumatologist.METHODS: Consecutive patients with IBD visiting the outpatient clinic were interviewed by a trained research nurse about possible SpA features using a standardized questionnaire regarding the presence or history of inflammatory back pain, peripheral arthritis, enthesitis, dactylitis, psoriasis, uveitis and response to nonsteroidal anti-inflammatory drugs. All patient files were verified for previous visits to a rheumatologist and any rheumatic diagnosis.RESULTS: At least one musculoskeletal SpA feature was reported by 129 of 350 (36.9%) patients. No significant differences between patients with Crohn disease and ulcerative colitis were found. Review of medical records showed that 66 (51.2%) patients had ever visited a rheumatologist. Axial SpA was diagnosed in 18 (27.3%) patients, peripheral SpA in 20 (30.3%) patients and another rheumatic disorder in 14 (21.2%) patients.CONCLUSION: Musculoskeletal SpA features are frequently present in patients with IBD. However, a substantial group of patients is not evaluated by a rheumatologist. Gastroenterologists play a key role in early referral of this often debilitating disease.

Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence

2017 ◽  
Vol 10 (4) ◽  
pp. 391-400 ◽  
Author(s):  
Sean McConachie ◽  
Sheila M. Wilhelm ◽  
Pramodini B. Kale-Pradhan
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
Inflammatory Bowel

Clinical Evidence for Mobilization of Very Small Embryonic/Epiblast Like Stem Cells (VSEL-SCs) in Patients With Inflammatory Bowel Disease

2011 ◽  
Vol 140 (5) ◽  
pp. S-656
Author(s):  
Wojciech M. Marlicz ◽  
Wojciech Blogowski ◽  
Edyta Paczkowska ◽  
Magda Kucia ◽  
Malgorzata Lawniczak ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Stem Cells ◽  
Bowel Disease ◽  
Clinical Evidence ◽  
Inflammatory Bowel

scholarly journals Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in anin vivomodel

2017 ◽  
Vol 23 (23) ◽  
pp. 4200 ◽  
Author(s):  
Chiara Dianzani ◽  
Federica Foglietta ◽  
Benedetta Ferrara ◽  
Arianna Carolina Rosa ◽  
Elisabetta Muntoni ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Solid Lipid Nanoparticles ◽  
Lipid Nanoparticles ◽  
Solid Lipid ◽  
Inflammatory Bowel ◽  
Inflammatory Drugs ◽  
Anti Inflammatory
Sign in / Sign up

Export Citation Format

Share Document